TY - JOUR
T1 - Survival Benefit and Cost Savings from Compliance with a Simplified 3-Hour Sepsis Bundle in a Series of Prospective, Multisite, Observational Cohorts
AU - Leisman, Daniel E.
AU - Doerfler, Martin E.
AU - Ward, Mary Frances
AU - Masick, Kevin D.
AU - Wie, Benjamin J.
AU - Gribben, Jeanie L.
AU - Hamilton, Eric
AU - Klein, Zachary
AU - Bianculli, Andrea R.
AU - Akerman, Meredith B.
AU - D'Angelo, John K.
AU - D'Amore, Jason A.
N1 - Publisher Copyright:
© 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Objectives: To determine mortality and costs associated with adherence to an aggressive, 3-hour sepsis bundle versus noncompliance with greater than or equal to one bundle element for severe sepsis and septic shock patients. Design: Prospective, multisite, observational study following three sequential, independent cohorts, from a single U.S. health system, through their hospitalization. Setting: Cohort 1: five tertiary and six community hospitals. Cohort 2: single tertiary, academic medical center. Cohort 3: five tertiary and four community hospitals. Patients: Consecutive sample of all severe sepsis and septic shock patients (defined: infection, ≥ 2 systemic inflammatory response syndrome, and hypoperfusive organ dysfunction) identified by a quality initiative. The exposure was full 3-hour bundle compliance. Bundle elements are as follows: 1) blood cultures before antibiotics; 2) parenteral antibiotics administered less than or equal to 180 minutes from greater than or equal to two systemic inflammatory response syndrome "and" lactate ordered, or less than or equal to 60 minutes from "time-zero," whichever occurs earlier; 3) lactate result available less than or equal to 90 minutes postorder; and 4) 30 mL/kg IV crystalloid bolus initiated less than or equal to 30 minutes from "time-zero." Main outcomes were in-hospital mortality (all cohorts) and total direct costs (cohorts 2 and 3). Measurements and Main Results: Cohort 1: 5,819 total patients; 1,050 (18.0%) bundle compliant. Mortality: 604 (22.6%) versus 834 (26.5%); CI, 0.9-7.1%; adjusted odds ratio, 0.72; CI, 0.61-0.86; p value is less than 0.001. Cohort 2: 1,697 total patients; 739 (43.5%) bundle compliant. Mortality: 99 (13.4%) versus 171 (17.8%), CI, 1.0-7.9%; adjusted odds ratio, 0.60; CI, 0.44-0.80; p value is equal to 0.001. Mean costs: 14,845 versus 20,056; CI, -4,798 to -5,624; adjusted β, -2,851; CI, -4,880 to -822; p value is equal to 0.006. Cohort 3: 7,239 total patients; 2,115 (29.2%) bundle compliant. Mortality: 383 (18.1%) versus 1,078 (21.0%); CI, 0.9-4.9%; adjusted odds ratio, 0.84; CI, 0.73-0.96; p value is equal to 0.013. Mean costs: 17,885 versus 22,108; CI, -2,783 to -5,663; adjusted β, -1,423; CI, -2,574 to -272; p value is equal to 0.015. Conclusions: In three independent cohorts, 3-hour bundle compliance was associated with improved survival and cost savings.
AB - Objectives: To determine mortality and costs associated with adherence to an aggressive, 3-hour sepsis bundle versus noncompliance with greater than or equal to one bundle element for severe sepsis and septic shock patients. Design: Prospective, multisite, observational study following three sequential, independent cohorts, from a single U.S. health system, through their hospitalization. Setting: Cohort 1: five tertiary and six community hospitals. Cohort 2: single tertiary, academic medical center. Cohort 3: five tertiary and four community hospitals. Patients: Consecutive sample of all severe sepsis and septic shock patients (defined: infection, ≥ 2 systemic inflammatory response syndrome, and hypoperfusive organ dysfunction) identified by a quality initiative. The exposure was full 3-hour bundle compliance. Bundle elements are as follows: 1) blood cultures before antibiotics; 2) parenteral antibiotics administered less than or equal to 180 minutes from greater than or equal to two systemic inflammatory response syndrome "and" lactate ordered, or less than or equal to 60 minutes from "time-zero," whichever occurs earlier; 3) lactate result available less than or equal to 90 minutes postorder; and 4) 30 mL/kg IV crystalloid bolus initiated less than or equal to 30 minutes from "time-zero." Main outcomes were in-hospital mortality (all cohorts) and total direct costs (cohorts 2 and 3). Measurements and Main Results: Cohort 1: 5,819 total patients; 1,050 (18.0%) bundle compliant. Mortality: 604 (22.6%) versus 834 (26.5%); CI, 0.9-7.1%; adjusted odds ratio, 0.72; CI, 0.61-0.86; p value is less than 0.001. Cohort 2: 1,697 total patients; 739 (43.5%) bundle compliant. Mortality: 99 (13.4%) versus 171 (17.8%), CI, 1.0-7.9%; adjusted odds ratio, 0.60; CI, 0.44-0.80; p value is equal to 0.001. Mean costs: 14,845 versus 20,056; CI, -4,798 to -5,624; adjusted β, -2,851; CI, -4,880 to -822; p value is equal to 0.006. Cohort 3: 7,239 total patients; 2,115 (29.2%) bundle compliant. Mortality: 383 (18.1%) versus 1,078 (21.0%); CI, 0.9-4.9%; adjusted odds ratio, 0.84; CI, 0.73-0.96; p value is equal to 0.013. Mean costs: 17,885 versus 22,108; CI, -2,783 to -5,663; adjusted β, -1,423; CI, -2,574 to -272; p value is equal to 0.015. Conclusions: In three independent cohorts, 3-hour bundle compliance was associated with improved survival and cost savings.
KW - costs and cost analysis
KW - multiple organ failure
KW - sepsis
KW - septic shock
KW - systemic inflammatory response
UR - http://www.scopus.com/inward/record.url?scp=85004024040&partnerID=8YFLogxK
U2 - 10.1097/CCM.0000000000002184
DO - 10.1097/CCM.0000000000002184
M3 - Article
C2 - 27941371
AN - SCOPUS:85004024040
SN - 0090-3493
VL - 45
SP - 395
EP - 406
JO - Critical Care Medicine
JF - Critical Care Medicine
IS - 3
ER -